Solanezumab

N/A

Report date: 2023/03/13 13:58:55

Base Information

Drug NameSolanezumab
Drug Alias NameSolanezumabum (Lilly)茄尼醇单抗Anti-Aβ monoclonal antibody (Lilly)苏兰珠单抗索拉奈珠单抗 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCognition DisordersAlzheimer DiseaseDementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[21] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyAvid Radiopharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCognition DisordersAlzheimer DiseaseDementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG